Navigation Links
Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium

WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today released its updated Pharmacor Rheumatoid Arthritis report which now includes patient share and sales forecasts through 2018 for Rigel Pharmaceuticals' investigational novel oral agent, fostamatinib disodium (R788). The report update is based on Rigel Pharmaceuticals' recent announcement regarding additional Phase II clinical data for fostamatinib disodium.

The report finds that, owing to its impressive efficacy, the spleen tyrosine kinase (Syk) inhibitor fostamatinib disodium will likely precede TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira in the treatment cascade for rheumatoid arthritis. Phase II data shows that fostamatinib disodium's efficacy is comparable to that of currently-available biologic agents in patients with inadequate response to treatment with methotrexate. According to the report, if the agent is priced lower than currently-available biologics, physicians may be willing to prescribe fostamatinib disodium as an alternative to premium-priced biologics.

However, Decision Resources conservatively forecasts that fostamatinib disodium's patient share will reach up to 1.8 percent and it will garner major-market sales of $330 million in 2018.

"Fostamatinib disodium's patient share and sales will be considerably lower than our evaluation of the other novel oral agent in development for rheumatoid arthritis--Pfizer's Jak-3 inhibitor CP-690550," said Decision Resources Analyst Joanna Kim, M.Ed. "Fostamatinib disodium's impact is likely to be less than that of CP-690550 because of uncertainties about its efficacy in the TNF-refractory population and the absence of a head-to-head trial against a TNF-alpha inhibitor."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563          

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BCBSGA Announces Decision to Cover H1N1 Vaccine Administration
2. PET can help guide treatment decisions for a common pediatric cancer
3. WellPoint Announces Decision to Cover H1N1 Vaccine Administration
4. United States Patent Office Issues Decision in Re-examination Proceedings
5. Providence Service Corporation Comments on U.S. Court of Appeals Decision to Uphold Federal Injunction Blocking Californias 10% Cut in Medi-Cal Payments
6. Stem Cell Decision Opens New Doors, May Spur More Research
7. TriServ Likely to Protest Decision
8. Communicating science to decision makers
9. Brain section multitasks, handling phonetics and decision-making
10. The decision about the incision: Is midline or transverse better for abdominal surgery?
11. Jeff Stewart Joins Decision Resources, Inc. as Chief Information Officer
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled for ... , For 65 years, Brillianteen has been a treasured tradition for ...
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Students and ... were awarded to winners of the Create Real Impact awards. California Casualty ... to help stem the tide of distracted and reckless driving, the number one killer ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Research ... of the "Membranes Market - Global Forecast to ... Asia-Pacific , accounting for 37.21% of the ... Asia-Pacific region is projected to ... This growth has been attributed primarily to the fast ...
(Date:11/25/2015)... 25, 2015 ... of the  "Global Drug Device Combination ... their offering.  --> ... the  "Global Drug Device Combination Products ... offering.  --> Research and ...
(Date:11/24/2015)... -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") ... and technology platform company serving the pharmaceutical, biotechnology, and ... and the United States ... of shareholders held today, the Company,s shareholders voted in ... previously announced agreement and plan of merger (the "Merger ...
Breaking Medicine Technology: